SAN MATEO, CA. – June 08, 2026 – Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical data for KT209, its novel trispecific antibody candidate, will be presented in a poster session at the European Hematology Association (EHA 2026) Annual Congress. KT209 is a novel trispecific antibody engineered to co-engage CD19, CD20, and CD3, redirecting endogenous T cells to ac

SAN MATEO, CA. – May 12, 2026 – Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, announced that preclinical data for KT502, its second therapeutic candidate, has been accepted for an oral presentation at the European Congress of Rheumatology (EULAR 2026). The congress will be held from June 3–6, 2026, in London, United Kingdom. KT502 is a high-potency CD19 x CD3 bispecific T-cell engager (TCE) designed to achieve

SAN MATEO, CA. – March 23, 2026 –Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with Sanofi for a tri-specific T-cell engager, which has the potential to treat a broad range of B cell-mediated autoimmune diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to KT501, a novel tri-specific antibody utilizing Kali Therapeutics’

SAN MATEO, Calif. – March 18, 2026 – Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, today announced that dosing is underway for the first cohort of patients in its Phase 1a clinical trial evaluating KT501. KT501 is a first-in-class CD19xBCMAxCD3 trispecific T-cell engager (TCE). The study is being conducted in adult patients with Rheumatoid Arthritis (RA). A Transformative Milestone for Kali Therapeutics The d

Kali Therapeutics Announces Upcoming Poster Presentations at the American College of Rheumatology (ACR) Convergence 2025